Gland Pharma (NSE:GLAND) Total Inventories : ₹16,552 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Total Inventories?

Gland Pharma's total inventories for the quarter that ended in Mar. 2024 was ₹16,552 Mil. Gland Pharma's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was ₹8,276 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Gland Pharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was ₹130.57.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Gland Pharma's Days Inventory for the three months ended in Mar. 2024 was 126.00.

Inventory Turnover measures how fast the company turns over its inventory within a year. Gland Pharma's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.72.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Gland Pharma's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.54.

Gland Pharma Total Inventories Historical Data

The historical data trend for Gland Pharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Total Inventories Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Inventories

Get a 7-Day Free Trial

7,562.79

12,751.68

11,856.67

19,453.00

16,552.37

Gland Pharma Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															19,453.00	-	20,843.48	-	16,552.37

Gland Pharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Gland Pharma (NSE:GLAND) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Gland Pharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(20913.66	+	0.75 * 15586.9	+	0.5 * 16552.37	-	19374.03
-	0	-	0)	/	164.711
=	130.57

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Gland Pharma's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	8276.185	/	5993.82	*	365 / 4
	=	126.00

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Gland Pharma's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	5993.82	/	8276.185
	=	0.72

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Gland Pharma's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	8276.185	/	15374.5
	=	0.54

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Gland Pharma Total Inventories Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Gland Pharma (NSE:GLAND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

543245:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines